<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02466789</url>
  </required_header>
  <id_info>
    <org_study_id>H14-25321</org_study_id>
    <nct_id>NCT02466789</nct_id>
  </id_info>
  <brief_title>Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)</brief_title>
  <acronym>VWF-phV</acronym>
  <official_title>Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonathan Roberts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Blood Center of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bleeding and Clotting Disorders Institute Peoria, Illinois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve the investigators ability to diagnose von Willebrand
      Disease (VWD), a common inherited bleeding disorder. This study will look at a new screening
      blood test used to determine if a person has VWD. This new screening blood test can determine
      a diagnosis more rapidly than current blood tests. Also this test could be available at local
      hospital labs rather than require samples to be sent to bigger more specialized labs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This investigation will be a prospective, multicenter trial to validate the clinical utility
      of a novel screening assay as a diagnostic screening assay for VWD variants: Type 1C, 2A, 2B,
      2M and 2N. Once the subject is enrolled into the study, a minimum of 0.5ml of citrated plasma
      will be collected and analyzed at the Bleeding and Clotting Disorders Institute Laboratory in
      Peoria Illinois. Results will be collected: phenotype function profiles will be determined,
      statistically analyzed and compared to the qualitative data from Blood Center of Wisconsin.
      Data is expected to correlate as previously shown in prior studies and will confirm the
      utility of this assay.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validate the novel ELISA-based VWF functional screening assay as a diagnostic screening assay to assign VWD phenotypes 1C, 2A, 2B, 2M and 2N.</measure>
    <time_frame>planned analysis at 2 years and 4 years with study duration estimated at 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Further development of the VWF functional screening assay through investigating the incorporation of VWF:CB6 (binding to collagen VI)</measure>
    <time_frame>study duration 4 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Von Willebrands Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sodium Citrated Plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        New subjects undergoing evaluation for the diagnosis of VWD that are determined to have
        VWF:ag or VWF:RCo &lt;50 IU/dl and or a VWF:RCo/VWF:ag ratio of &lt;0.7. Also subjects will be
        included if Type 2N VWD is suspected
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New subjects undergoing evaluation for the diagnosis of VWD determined to have a
             VWF:Ag or VWF: RCo &lt; 50 IU/dl and or a VWF:RCo/VWF:Ag of &lt;0.7. Also subjects will be
             included if Type 2 N VWD is clinically suspected

        Exclusion Criteria:

          -  Those subjects whose lab results do not meet the inclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Roberts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bleeding and Clotting Disorders Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Roberts, MD</last_name>
    <phone>309-692-5337</phone>
    <phone_ext>123</phone_ext>
    <email>jroberts@ilbcdi.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Gonzales, BS</last_name>
    <phone>309-692-5337</phone>
    <phone_ext>135</phone_ext>
    <email>sgonzales@ilbcdi.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Roberts, MD</last_name>
      <phone>309-692-5337</phone>
      <phone_ext>123</phone_ext>
      <email>jroberts@ilbcdi.org</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Gonzales, BS</last_name>
      <phone>309-692-5337</phone>
      <phone_ext>135</phone_ext>
      <email>sgonzales@ilbcdi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael D Tarantino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008 Mar;14(2):171-232. doi: 10.1111/j.1365-2516.2007.01643.x.</citation>
    <PMID>18315614</PMID>
  </reference>
  <reference>
    <citation>Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987 Feb;69(2):454-9.</citation>
    <PMID>3492222</PMID>
  </reference>
  <reference>
    <citation>Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993 Dec;123(6):893-8.</citation>
    <PMID>8229521</PMID>
  </reference>
  <reference>
    <citation>Werner EJ, Abshire TC, Giroux DS, Tucker EL, Broxson EH. Relative value of diagnostic studies for von Willebrand disease. J Pediatr. 1992 Jul;121(1):34-8.</citation>
    <PMID>1625090</PMID>
  </reference>
  <reference>
    <citation>Castaman G, Eikenboom JC, Bertina RM, Rodeghiero F. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation. Thromb Haemost. 1999 Sep;82(3):1065-70.</citation>
    <PMID>10494765</PMID>
  </reference>
  <reference>
    <citation>Rodeghiero F, Castaman G, Tosetto A. von Willebrand factor antigen is less sensitive than ristocetin cofactor for the diagnosis of type I von Willebrand disease--results based on an epidemiological investigation. Thromb Haemost. 1990 Nov 30;64(3):349-52.</citation>
    <PMID>2096485</PMID>
  </reference>
  <reference>
    <citation>Bazhan SV, Zhdanov VP, Koshil' OI. [Experience in organizing rehabilitative treatment for infectious patients]. Voen Med Zh. 1991 Jul;(7):35-6. Russian.</citation>
    <PMID>1835556</PMID>
  </reference>
  <reference>
    <citation>Castaman G, Tosetto A, Goodeve A, Federici AB, Lethagen S, Budde U, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Habart D, Hill F, Peake I, Rodeghiero F. The impact of bleeding history, von Willebrand factor and PFA-100(Â®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol. 2010 Nov;151(3):245-51. doi: 10.1111/j.1365-2141.2010.08333.x. Epub 2010 Aug 25.</citation>
    <PMID>20738304</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood. 2009 Jan 15;113(3):526-34. doi: 10.1182/blood-2008-04-152280. Epub 2008 Sep 19.</citation>
    <PMID>18805962</PMID>
  </reference>
  <reference>
    <citation>Federici AB, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica. 2009 May;94(5):610-5. doi: 10.3324/haematol.2009.005751.</citation>
    <PMID>19407316</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2015</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bleeding and Clotting Disorders Institute Peoria, Illinois</investigator_affiliation>
    <investigator_full_name>Jonathan Roberts</investigator_full_name>
    <investigator_title>Assistant Research Director</investigator_title>
  </responsible_party>
  <keyword>Bleeding Disorder, inherited</keyword>
  <keyword>Von Willebrands Disease</keyword>
  <keyword>Hematologic Test</keyword>
  <keyword>VWF</keyword>
  <keyword>VWD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

